Marker Therapeutics, Inc.

Tagged: Sachs

TapImmune to Participate in Two Upcoming Investor and Industry Conferences

Dr. Glynn Wilson, Chairman and CEO of TapImmune, will provide an overview of the company’s business, clinical pipeline and partnering opportunities for its proprietary PolyStart technology platform during his presentation at the 5th Annual Cancer Biopartnering & Investment Forum

Read More